

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 November 2020 (19.11.2020)



(10) International Publication Number
WO 2020/232154 A2

(51) International Patent Classification:
A61K 31/5377 (2006.01)

(21) International Application Number:
PCT/US2020/032722

(22) International Filing Date:
13 May 2020 (13.05.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/847,810 14 May 2019 (14.05.2019) US
62/855,910 31 May 2019 (31.05.2019) US

(71) Applicant: **SIERRA ONCOLOGY, INC.** [US/US];
Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US).

(72) Inventors: **HASSIG, Christian, Andrew**; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). **STROUSE, Bryan, William**; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). **HANSEN, Ryan, James**; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). **ANDERES, Kenna, Lynn**; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). **MILUTINOVIC, Snezana**; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). **YOU, Angie, J.**; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). **KLENCKE, Barbara**; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US). **KOWALSKI, Mark**; c/o Sierra Oncology, Inc., Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170 (US).

(74) Agent: **FOULDS, Glenn, J.** et al.; Fenwick & West LLP, 801 California Street, Mountain View, CA 94041 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))



WO 2020/232154 A2

(54) Title: METHODS OF TREATING CANCER USING CHK1 INHIBITORS

(57) Abstract: This disclosure provides methods of using a checkpoint kinase 1 (Chk1) inhibitor in the treatment of cancer in a subject having at least an intermediate tumor mutational burden (TMB), or a genetic abnormality in one or more particular genes associated with replicative stress. Accordingly, methods of treating cancer in a subject having at least an intermediate tumor mutational burden (TMB-I) are provided. Also provided are methods of treating cancer in a subject having a genetic abnormality in one or more particular genes selected from cell cycle regulation genes, replication stress genes, oncogenic driver mutations and DNA damage response and repair network genes. Methods of selecting subjects for Chk1 inhibition therapy are provided. The methods can include administering to the subject an effective amount of a SRA737 compound, in some cases in combination with low dose gemcitabine.